drugset
drugset / Trial / NCT03144934

Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

NCT03144934 ↗

Phase 1 Completed 32 enrolled Genexine, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of GX-I7 in HPV-infected female volunteers

Timeline

Start
2017-02-16
Primary completion
2018-03-22
Completion
2018-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject NT-I7 Protein / enzyme biologic 0.25 mg Intravenous
Subject NT-I7 Protein / enzyme biologic 1 mg Intravenous
Subject NT-I7 Protein / enzyme biologic 3 mg Intravenous
Subject NT-I7 Protein / enzyme biologic 6 mg Intravenous
Subject NT-I7 Protein / enzyme biologic 9 mg Intravenous

Indications

human papilloma virus infection